Wynzora® Cream (calcipotriene 0.005% and betamethasone dipropionate 0.064%) is now available for the topical treatment of plaque psoriasis in adults 18 years of age and older.
Wynzora is a combination of calcipotriene, a synthetic vitamin D3 analogue, and betamethasone dipropionate, a corticosteroid. Each gram of Wynzora Cream contains 50mcg of calcipotriene and 0.644mg of betamethasone dipropionate.
The approval of the aqueous formulation was based on data from a phase 3 trial that evaluated the efficacy, safety, and convenience of Wynzora in 794 patients with mild to moderate plaque psoriasis. Treatment with Wynzora was found to be superior to placebo and noninferior to calcipotriene/betamethasone dipropionate topical suspension.
Regarding safety, the most common adverse reactions observed with Wynzora were upper respiratory infection, headache, and application site irritation.
Wynzora is applied once daily to affected areas for up to 8 weeks; no more than 100g should be used per week. The product is supplied in 60g tubes.
- EPI Health and MC2 Therapeutics announces US launch of Wynzora® Cream for plaque psoriasis (calcipotriene and betamethasone dipropionate w/w 0.005%/0.064%). News release. Accessed July 19, 2021. https://www.prnewswire.com/news-releases/epi-health-and-mc2-therapeutics-announces-us-launch-of-wynzora-cream-for-plaque-psoriasis-calcipotriene-and-betamethasone-dipropionate-ww-0-0050-064-301332247.html.
- Wynzora [package insert]. Charleston, SC: EPI Health. 2021.
This article originally appeared on MPR